Fosun Health Capital reached a cooperation agreement with Medicilon to explore innovative drug research and development together
On July 25, 2023, Fosun Health Capital established by Fosun Pharma（stock code:600196.SH), reached a strategic partnership with Medicilon（stock code: 688202.SH). Meanwhile StarMab Biology (Suzhou) ( referred to as "StarMab Biology"，jointly invested by the innovation drug research fund of Fosun Group and Yaopharma) and Medicilon entered into a strategic cooperation for innovative drug IND research and application services. This strategic partnership indicates a significant step forward in the cooperation between Fosun Health Capital and Medicilon, with milestone for both parties' development. Cui Zhiping, Co-CEO and General Manager of Fosun Health Capital, Chen Chunlin, Founder and CEO of Medicilon, along with members from both sides attended the signing ceremony together and witnessed the contract. According to the strategic cooperation agreement, Medicilon will leverage its international perspective and rich experience in R&D to provide innovative drug enterprises i...